Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
A Study of the Efficacy and Safety of Desloratadine (MK-4117) in Japanese Participants With Perennial Allergic Rhinitis (MK-4117-200)
Phase 3
Completed
- Conditions
- Perennial Allergic Rhinitis
- Interventions
- Drug: Desloratadine 5 mgDrug: Placebo
- First Posted Date
- 2013-08-07
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 608
- Registration Number
- NCT01918033
Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Eczema/Dermatitis and Dermal Pruritus (MK-4117-202)
- First Posted Date
- 2013-08-06
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 94
- Registration Number
- NCT01916980
An Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Chronic Urticaria (MK-4117-201)
- First Posted Date
- 2013-08-06
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 239
- Registration Number
- NCT01916967
Study of the Efficacy and Safety of MK-0476 in Japanese Pediatric Participants With Seasonal Allergic Rhinitis (MK-0476-519)
- First Posted Date
- 2013-05-20
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 220
- Registration Number
- NCT01857063
Study of the Safety and Pharmacokinetics of Montelukast (MK-0476) in the Treatment of Japanese Pediatric Participants With Perennial Allergic Rhinitis (MK-0476-520)
Phase 3
Completed
- Conditions
- Perennial Allergic Rhinitis
- Interventions
- First Posted Date
- 2013-05-14
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 87
- Registration Number
- NCT01852812
Efficacy and Safety of Oral NOMAC-E2 in Indian Women (P07057/MK-8175A-017)
Phase 3
Withdrawn
- Conditions
- Contraception
- Interventions
- First Posted Date
- 2012-11-08
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Organon and Co
- Registration Number
- NCT01723579
A Dose-Finding Study to Evaluate Ovarian Function and Vaginal Bleeding in Next Generation Rings (P06109/MK-8175A/MK-8342B-012)
Phase 2
Completed
- Conditions
- Contraception
- Interventions
- First Posted Date
- 2012-10-18
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 666
- Registration Number
- NCT01709318
A Study of the Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adult Men With Hypogonadotropic Hypogonadism (HH) (P07937)
Phase 3
Completed
- Conditions
- HypogonadismHypogonadotropic Hypogonadism
- Interventions
- First Posted Date
- 2012-10-18
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 18
- Registration Number
- NCT01709331
Finasteride (MK-0906) and Male Breast Cancer - A Register-Based Nested Case-Control Study (MK-0906-162/2003.021).
Completed
- Conditions
- Male Breast Cancer
- First Posted Date
- 2012-10-10
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 575216
- Registration Number
- NCT01703520
Etoricoxib Prescribing Patterns and Adverse Events of Interest in Primary Care in the United Kingdom (MK-0663-162 AM1)
Completed
- Conditions
- OsteoarthritisAnkylosing SpondylitisGoutArthritisRheumatoid Arthritis
- Interventions
- First Posted Date
- 2012-09-14
- Last Posted Date
- 2022-02-18
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 79189
- Registration Number
- NCT01685424
© Copyright 2025. All Rights Reserved by MedPath